These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30529793)

  • 21. Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial.
    Mardešič T; Mannaerts B; Abuzeid M; Levy M; Witjes H; Fauser BC;
    Reprod Biomed Online; 2014 Apr; 28(4):462-8. PubMed ID: 24581989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study.
    Polyzos NP; Devos M; Humaidan P; Stoop D; Ortega-Hrepich C; Devroey P; Tournaye H
    Fertil Steril; 2013 Feb; 99(2):422-6. PubMed ID: 23084565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.
    Oehninger S; Nelson SM; Verweij P; Stegmann BJ
    Reprod Biol Endocrinol; 2015 Oct; 13():117. PubMed ID: 26520396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant follicle-stimulating hormone on follicular fluid levels of adhesion molecules during in vitro fertilization.
    Fornaro F; Cobellis L; Mele D; Tassou A; Badolati B; Sorrentino S; De Lucia D; Colacurci N
    Fertil Steril; 2007 Jan; 87(1):39-47. PubMed ID: 17084393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis.
    Mahmoud Youssef MA; van Wely M; Aboulfoutouh I; El-Khyat W; van der Veen F; Al-Inany H
    Fertil Steril; 2012 Apr; 97(4):876-85. PubMed ID: 22277766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for oocyte donors].
    Benchabane M; Santulli P; Maignien C; Bourdon M; De Ziegler D; Chapron C; Gayet V
    Gynecol Obstet Fertil Senol; 2017 Feb; 45(2):83-88. PubMed ID: 28368800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women.
    Corifollitropin alfa Ensure Study Group
    Reprod Biomed Online; 2010 Jul; 21(1):66-76. PubMed ID: 20483664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation.
    Corifollitropin Alfa Dose-finding Study Group
    Hum Reprod; 2008 Nov; 23(11):2484-92. PubMed ID: 18684735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
    Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
    Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles.
    Yang C; Dong N; Li F; Ji Y; Pan Y; She H
    J Ovarian Res; 2022 Jun; 15(1):74. PubMed ID: 35729654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case-control study.
    Revelli A; Pittatore G; Casano S; Canosa S; Evangelista F; Benedetto C
    J Assist Reprod Genet; 2015 Mar; 32(3):429-34. PubMed ID: 25588963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial.
    Boostanfar R; Gates D; Guan Y; Gordon K; McCrary Sisk C; Stegmann BJ
    Fertil Steril; 2016 Aug; 106(2):300-305.e5. PubMed ID: 27090863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial.
    Fatemi HM; Oberyé J; Popovic-Todorovic B; Witjes H; Mannaerts B; Devroey P
    Fertil Steril; 2010 Oct; 94(5):1922-4. PubMed ID: 20149360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study.
    Tsakiridis I; Najdecki R; Tatsi P; Timotheou E; Kalinderi K; Michos G; Virgiliou A; Yarali H; Athanasiadis A; Papanikolaou EG
    JBRA Assist Reprod; 2020 Oct; 24(4):436-441. PubMed ID: 32489086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antral follicle responsiveness to follicle-stimulating hormone administration assessed by the Follicular Output RaTe (FORT) may predict in vitro fertilization-embryo transfer outcome.
    Gallot V; Berwanger da Silva AL; Genro V; Grynberg M; Frydman N; Fanchin R
    Hum Reprod; 2012 Apr; 27(4):1066-72. PubMed ID: 22279090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.
    Fauser BC; Mannaerts BM; Devroey P; Leader A; Boime I; Baird DT
    Hum Reprod Update; 2009; 15(3):309-21. PubMed ID: 19182099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antral follicle responsiveness assessed by follicular output RaTe(FORT) correlates with follicles diameter.
    Bessow C; Donato R; de Souza T; Chapon R; Genro V; Cunha-Filho JS
    J Ovarian Res; 2019 May; 12(1):48. PubMed ID: 31128593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial.
    Leader A; Devroey P; Witjes H; Gordon K
    Reprod Biol Endocrinol; 2013 Jun; 11():52. PubMed ID: 23758821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome.
    Bonduelle M; Mannaerts B; Leader A; Bergh C; Passier D; Devroey P
    Hum Reprod; 2012 Jul; 27(7):2177-85. PubMed ID: 22587997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.